“`html
New Cervical Cancer Screening Guidelines: A 2026 Update
At teh end of 2025, the American Cancer Society (ACS) released its new cervical cancer screening guidelines. In January 2026, the Health Resources and Services Administration (HRSA), part of the Health and Human Services Department (HHS), endorsed a new set of guidelines as well. These updates represent a significant shift in how cervical cancer is prevented, focusing more heavily on HPV testing.
The two sets of guidelines largely align, but some key differences exist. This article breaks down the recommendations, highlighting areas of consensus and divergence, to provide a clear understanding of the latest best practices.
Where the Guidelines Agree
- The HPV Primary Test is Preferred.Both groups recommend that providers use an HPV primary test for patients of average risk from the age of 30-65. This test looks for the types of HPV (human papillomavirus) that are known to cause about 70% of cervical cancers. If the HPV primary test is not available, the groups recommend co-testing.
- Screening Interval for HPV-Positive Results: If an HPV primary test is positive, both organizations recommend reflex cytology (a Pap test) to determine next steps.
- Screening Can Stop Earlier: Both ACS and HRSA agree that individuals who are 65 or older, and have had adequate prior screening, can stop cervical cancer screening.
- Importance of Vaccination: Both emphasize the critical role of HPV vaccination in preventing cervical cancer.
Key Differences in Recommendations
Starting Age for Screening
This is the most notable difference. The ACS recommends starting regular screening at age 25, while HRSA suggests beginning at age 21 with a Pap test. HRSA’s guidelines state that HPV primary screening should begin at age 30.
Co-Testing Frequency
When co-testing (Pap test and HPV test) is performed, the ACS recommends doing so every five years. HRSA suggests co-testing every three years.
Follow-Up for Abnormal Results
While both agree on the general approach to follow-up for abnormal results, there are slight variations in the specific criteria and timelines for colposcopy (a procedure to examine the cervix more closely).
Understanding the Rationale Behind the Changes
The shift towards HPV primary testing is driven by several factors:
- Higher Accuracy: HPV tests are more sensitive than Pap tests in detecting precancerous changes.
- Reduced Colposcopy Rates: Using HPV primary testing can reduce the number of unnecessary colposcopies.
- Improved Risk Stratification: HPV testing provides a clearer picture of a patient’s risk for developing cervical cancer.
What These Guidelines Mean for Patients
These updated guidelines aim to provide more effective and efficient cervical cancer screening. Patients should discuss their individual risk factors and screening options with their healthcare provider to determine the best approach. It’s crucial to understand that these are guidelines, and personalized care is paramount.
FAQ
Q: What is HPV primary testing?
A: HPV primary testing looks for the presence of high-risk types of HPV in a cervical sample.It’s more sensitive than a pap test for detecting precancerous changes.
Q: What if the HPV primary test is positive?
A: A positive HPV primary test usually leads to a reflex cytology test (Pap test) to further evaluate the cells.
Q: When can I stop getting screened for cervical cancer?
A: Both ACS and HRSA agree that you can generally stop screening at age 65 if you’ve had adequate prior screening.
